Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;43(9):2369-75.
doi: 10.1161/STROKEAHA.112.660993. Epub 2012 Jul 12.

Impact of acute ischemic stroke treatment in patients >80 years of age: the specialized program of translational research in acute stroke (SPOTRIAS) consortium experience

Affiliations

Impact of acute ischemic stroke treatment in patients >80 years of age: the specialized program of translational research in acute stroke (SPOTRIAS) consortium experience

Joshua Z Willey et al. Stroke. 2012 Sep.

Abstract

Background and purpose: Few studies have addressed outcomes among patients ≥80 years treated with acute stroke therapy. In this study, we outline in-hospital outcomes in (1) patients ≥80 years compared with their younger counterparts; and (2) those over >80 years receiving intra-arterial therapy (IAT) compared with those treated with intravenous recombinant tissue-type plasminogen activator (IV rtPA).

Methods: Stroke centers within the Specialized Program of Translational Research in Acute Stroke (SPOTRIAS) prospectively collected data on all patients treated with IV rtPA or IAT from January 1, 2005, to December 31, 2010. IAT was defined as receiving any endovascular therapy; IAT was further divided into bridging therapy when the patient received both IAT and IV rtPA and endovascular therapy alone. In-hospital mortality was compared in (1) all patients aged ≥80 years versus younger counterparts; and (2) IAT, bridging therapy, and endovascular therapy alone versus IV rtPA only among those age ≥80 years using multivariable logistic regression. An age-stratified analysis was also performed.

Results: A total of 3768 patients were included in the study; 3378 were treated with IV rtPA alone and 808 with IAT (383 with endovascular therapy alone and 425 with bridging therapy). Patients ≥80 years (n=1182) had a higher risk of in-hospital mortality compared with younger counterparts regardless of treatment modality (OR, 2.13; 95% CI, 1.60-2.84). When limited to those aged ≥80 years, IAT (OR, 0.95; 95% CI, 0.60-1.49), bridging therapy (OR, 0.82; 95% CI, 0.47-1.45), or endovascular therapy alone (OR, 1.15; 95% CI, 0.64-2.08) versus IV rtPA were not associated with increased in-hospital mortality.

Conclusions: IAT does not appear to increase the risk of in-hospital mortality among those aged >80 years compared with IV thrombolysis alone.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Age effect on In-hospital mortality in different acute stroke therapies
IV rtPA: intravenous recombinant tissue plasminogen activator alone IAT: any intra-arterial therapy ETA: endovascular therapy alone Ref: reference category Unadjusted: univariate analysis Adjusted: Multivariable adjusted for sex, race-ethnicity, and SPOTRIAS center, national institutes of health stroke scale and serum glucose level.
Figure 2
Figure 2. Age effect on discharge disposition other than home in different acute stroke therapies
IV rtPA: intravenous recombinant tissue plasminogen activator alone IAT: any intra-arterial therapy ETA: endovascular therapy alone Ref: reference category Unadjusted: univariate analysis Adjusted: Multivariable analysis adjusted for sex, race-ethnicity, and SPOTRIAS center, national institutes of health stroke scale and serum glucose level.

References

    1. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart disease and stroke statistics--2008 update: A report from the american heart association statistics committee and stroke statistics subcommittee. Circulation. 2008;117:e25–146. - PubMed
    1. Lindley RI, Wardlaw JM, Sandercock PA. Thrombolysis in elderly people. Observational data insufficient to change treatment. BMJ. 2011;342:d306. author reply d312. - PubMed
    1. Fonarow GC, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Grau-Sepulveda MV, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: Patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011;123:750–758. - PubMed
    1. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. The New England journal of medicine. 2008;359:1317–1329. - PubMed
    1. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The proact ii study: A randomized controlled trial. Prolyse in acute cerebral thromboembolism. Jama. 1999;282:2003–2011. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources